Form 4: Axsome Therapeutics Director Roger Jeffs Executes Stock Options and Sells Shares Under 10b5-1 Plan

Director Roger Jeffs exercised stock options and sold shares of Axsome Therapeutics (AXSM) common stock on March 14-15, 2024, under a pre-approved 10b5-1 trading plan.

Summary

• Roger Jeffs, a director of Axsome Therapeutics, executed stock options and sold shares of the company's common stock on March 14 and 15, 2024.
• The transactions were conducted under a pre-approved 10b5-1 trading plan.
• On March 14, Jeffs exercised options to acquire 13,000 shares at $22.03 and sold those shares at $69.702.
• Also on March 14, Jeffs exercised options to acquire 16,976 shares at $25.53 and sold those shares at $69.702.
• On March 15, Jeffs exercised options to acquire 2,347 shares at $29.91 and sold those shares at $71.6072.
• Following these transactions, Jeffs directly owns 120,756 shares of Axsome Therapeutics common stock.
• Jeffs also indirectly owns 46,912 shares through a GRAT.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, detailing stock option exercises and sales by a company director. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure. The transactions are part of a pre-approved plan, further neutralizing the sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares over a predetermined period, mitigating concerns about insider trading. Investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Comparing Roger Jeffs' transactions to similar insider sales at comparable biotech companies like Biogen (BIIB) or Vertex Pharmaceuticals (VRTX) would require analyzing the size and frequency of their insider transactions.
• A typical benchmark for evaluating insider transactions is to compare the ratio of insider sales to purchases.
• A high ratio of sales to purchases might indicate a lack of confidence in the company's future prospects, while a low ratio could suggest the opposite.
• However, it's important to consider that insider sales can be driven by various personal financial planning reasons and may not always reflect the insider's view of the company's prospects.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price due to the increased supply of shares in the market.
• However, the impact is likely to be limited, given the relatively small volume of shares involved and the fact that the transactions were pre-planned.

Key Dates